readthroughSign in
Sep 30, 2026Financing

Nomad Power Solutions raises $6.0 million via secured note, with Lixte as guarantor subsidiary

SEC filing indexed under Lixte Biotechnology Holdings actually names Nomad Power Solutions, Inc. as the registrant entering the financing.

A Form 8-K dated for an event on September 28, 2026 was filed under SEC EDGAR indexing for Lixte Biotechnology Holdings, Inc., but the body of the filing identifies the registrant as Nomad Power Solutions, Inc., trading under the symbol NMAD on Nasdaq. The document itself contains this inconsistency between its header source label and its stated registrant.

According to the filing, on September 28, 2026, Nomad Power Solutions, Inc. entered into a Note Purchase Agreement with an Accredited Investor, pursuant to which the Company agreed to issue and sell in a private placement an aggregate principal amount of $6.57 million Original Issue Discount Secured Promissory Note for aggregate gross proceeds of $6.0 million.1 The note carries terms specified in the filing: the Note carries an original issue discount of 540,000, the Company agreed to pay $30,000 to cover fees and expenses, and the maturity date of the Note is 12 months from the Purchase Price Date with an interest rate of nine percent per year until paid in full.1

Starting six months after the purchase price date, the purchaser has the right, exercisable at any time in its sole and absolute discretion, to redeem up to $800,000 per calendar month by providing written notice, and the Company will have 2 trading days to pay the redemption amount in cash.1

The financing is secured. The Company and the Investor entered into a Security Agreement under which the Investor is granted a security interest in collateral that includes all equity interests of the Company, all goods and equipment owned by the Company, all accounts receivable, contract rights, and all other assets, goods and personal property of the Company.1

The filing also identifies corporate relationships tied to the guaranty. The Investor, the Company, and the Company's wholly owned subsidiaries Lixte Biotechnology, Inc. and Liora Technologies Europe Ltd. entered into a Guaranty Agreement under which the Guarantors guarantee the indebtedness, liabilities and obligations of the Company to the Investor.1

The offering was conducted under an exemption from registration. The issuance of the Note was made pursuant to the exemption from registration requirements under the Securities Act available under Section 4(a)(2) and/or Regulation D, given that the offering did not involve a public offering of securities.1 The 8-K was signed September 30, 2026 by Geordan Pursglove, President and Chief Executive Officer.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.